68921-91-5

Basic information

• Product Name: 4,6-dichloro-5-nitro-2-phenylpyrimidine
• Synonyms: Pyrimidine, 4,6-dichloro-5-nitro-2-phenyl-; 4,6-Dichloro-5-nitro-2-phenylpyrimidine
• CAS NO: 68921-91-5
• Molecular Formula: C₁₀H₅Cl₂N₃O₂
• Molecular Weight: 270.0716
• EINECS: 272-967-9
• Mol File: 68921-91-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 299.3°C at 760 mmHg
• Flash Point: 134.8°C
• Density: 1.526g/cm³
• Vapor Pressure: 0.00213mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: 4,6-dichloro-5-nitro-2-phenylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloro-5-nitro-2-phenylpyrimidine(68921-91-5)
• EPA Substance Registry System: 4,6-dichloro-5-nitro-2-phenylpyrimidine(68921-91-5)

Safety Data

• Hazardous Substances Data: 68921-91-5(Hazardous Substances Data)

Usage

General Description

4,6-dichloro-5-nitro-2-phenylpyrimidine is a chemical compound with the molecular formula C10H5Cl2N3O2. It is a pyrimidine derivative with two chlorine atoms, a nitro group, and a phenyl group attached to the pyrimidine ring. 4,6-dichloro-5-nitro-2-phenylpyrimidine is used as a building block in the synthesis of various pharmaceuticals and agricultural chemicals. It has been studied for its potential antimicrobial and antifungal properties, and it is also being investigated for its use as a herbicide. The compound's structure and properties make it a valuable intermediate in organic synthesis and drug discovery processes.

Upstream product

• 13566-71-7 2-Phenyl-4,6-dihydroxy-pyrimidine 
• 1670-14-0 benzamidine monohydrochloride 
• 29954-25-4 6-chloro-2-phenyl-3H-pyrimidin-4-one 
• 618-39-3 benzamidin 
• 68905-99-7 2-Phenyl-5-nitro-4,6-dihydroxy-pyrimidine 
• 63447-35-8 2-phenyl-1H-pyrimidine-4,6-dione 

Downstream Products

• 1415583-54-8 C₂₂H₃₃N₇O₂ 
• 1415583-40-2 C₂₃H₃₁N₇O₃ 
• 1415583-43-5 C₂₃H₃₁N₇O₂ 
• 1415583-53-7 C₂₂H₃₁N₇O₄ 
• 64398-69-2 4,6-bis-aziridin-1-yl-2-phenyl-pyrimidin-5-ylamine 

Relevant articles and documents

Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii

Opportunistic infections from pathogenic fungi present a major challenge to healthcare because of a very limited arsenal of antifungal drugs, an increasing population of immunosuppressed patients, and increased prevalence of resistant clinical strains due to overuse of the few available antifungals. Cryptococcal meningitis is a life-threatening opportunistic fungal infection caused by one of two species in the Cryptococcus genus, Cryptococcus neoformans and Cryptococcus gattii. Eighty percent of cryptococcosis diseases are caused by C. neoformans that is endemic in the environment. The standard of care is limited to old antifungals, and under a high standard of care, mortality remains between 10 and 30%. We have identified a series of 5-nitro-6-thiocyanatopyrimidine antifungal drug candidates using in vitro and computational machine learning approaches. These compounds can inhibit C. neoformans growth at submicromolar levels, are effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and are not antagonistic with currently approved antifungals.

2-aryl-8-oxodihydropurine derivative, process for the producing the same, medicinal compositions containing the same, and intermediates thereof

2-Aryl-8-oxodihydropurine derivative of the following formula (I): wherein W is H, lower alkyl, halogen, lower alkoxy, amino, mono- or di-lower alkylamino, or substituted or unsubstituted phenyl; X is H, lower alkyl, cycloalkyl-lower alkyl, substituted or unsubstituted phenyl-lower alkyl, lower alkenyl, carbamoyl, di-lower alkylcarbamoyl, or a group of the formula (Q): —CH(R3)CON(R1)(R2); Y is H, lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, lower alkenyl, substituted or unsubstituted phenyl-lower alkyl, or a group of the formula (Q): —CH(R3)CON(R1)(R2); A is substituted or unsubstituted phenyl, or substituted or unsubstituted heteroaryl; provided that when one of X and Y of the above formula (I) is the group of the formula (Q), then the other is the same groups for X or Y as described above except for the group of the formula (Q), or a pharmaceutically acceptable acid addition salt thereof. These compounds are useful for the prophylaxis or treatment of central nervous disorders such as anxiety-related diseases (neurosis, somatoform disorders, anxiety disorders, and others), depression, epilepsy, etc., or circulatory organs disorders such as angina pectoris, hypertension.

CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS

The invention encompasses a compound of the formula STR1 and the pharmaceutically acceptable non-toxic salts thereof wherein X, W, Y, R, and R2 are variables.These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine type drugs, and enhancement of alertness.